These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

710 related articles for article (PubMed ID: 31286275)

  • 21. Novel androgen axis systemic therapies for metastatic hormone-sensitive prostate cancer.
    Hahn AW; Hale P; Rathi N; Agarwal N
    Curr Opin Urol; 2017 Nov; 27(6):559-565. PubMed ID: 28816716
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Systemic and Tumor-directed Therapy for Oligorecurrent Metastatic Prostate Cancer (SATURN): Primary Endpoint Results from a Phase 2 Clinical Trial.
    Nikitas J; Rettig M; Shen J; Reiter R; Lee A; Steinberg ML; Valle LF; Sachdeva A; Romero T; Calais J; Czernin J; Nickols NG; Kishan AU
    Eur Urol; 2024 Jun; 85(6):517-520. PubMed ID: 38494380
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Patients with metastatic prostate cancer : Recommendations for primary hormonal or chemohormonal therapy].
    Ohlmann CH
    Urologe A; 2017 Nov; 56(11):1424-1429. PubMed ID: 28983763
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Real-world treatment of metastatic hormone-sensitive prostate cancer in the USA, Europe and Asia.
    Goebell PJ; Raina R; Chen S; Rege S; Shah R; Grossman JP; Waldeck AR
    Future Oncol; 2024 May; 20(14):903-918. PubMed ID: 38353055
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Personalizing approaches to the management of metastatic hormone sensitive prostate cancer: role of advanced imaging, genetics and therapeutics.
    Lokeshwar SD; Choksi AU; Haltstuch D; Rahman SN; Press BH; Syed J; Hurwitz ME; Kim IY; Leapman MS
    World J Urol; 2023 Aug; 41(8):2007-2019. PubMed ID: 37160450
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of Abiraterone Acetate and Docetaxel with Androgen Deprivation Therapy in High-risk and Metastatic Hormone-naïve Prostate Cancer: A Systematic Review and Network Meta-analysis.
    Wallis CJD; Klaassen Z; Bhindi B; Goldberg H; Chandrasekar T; Farrell AM; Boorjian SA; Kulkarni GS; Karnes RJ; Satkunasivam R
    Eur Urol; 2018 Jun; 73(6):834-844. PubMed ID: 29037513
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Abiraterone plus prednisone in patients with newly diagnosed high-risk metastatic hormone-sensitive prostate cancer (mHSPC)].
    Miller K
    Aktuelle Urol; 2019 Dec; 50(6):625-628. PubMed ID: 30919390
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impact of disease volume on survival efficacy of triplet therapy for metastatic hormone-sensitive prostate cancer: a systematic review, meta-analysis, and network meta-analysis.
    Matsukawa A; Rajwa P; Kawada T; Bekku K; Laukhtina E; Klemm J; Pradere B; Mori K; Karakiewicz PI; Kimura T; Chlosta P; Shariat SF; Yanagisawa T
    Int J Clin Oncol; 2024 Jun; 29(6):716-725. PubMed ID: 38582807
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Systemic treatment options for metastatic hormone-sensitive prostate cancer: making sense of the data.
    Baston C; Preda A; Guler-Margaritis SS; Sinescu I; Gingu C
    Curr Opin Urol; 2020 Jul; 30(4):576-583. PubMed ID: 32427630
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Systemic and tumor-directed therapy for oligometastatic prostate cancer: study protocol for a phase II trial for veterans with de novo oligometastatic disease.
    Parikh NR; Huiza C; Patel JS; Tsai S; Kalpage N; Thein M; Pitcher S; Lee SP; Inouye WS; Jordan ML; Sanati H; Jafari L; Bennett CJ; Gin GE; Kishan AU; Reiter RE; Lewis M; Sadeghi A; Aronson WJ; Garraway IP; Rettig MB; Nickols NG
    BMC Cancer; 2019 Apr; 19(1):291. PubMed ID: 30935383
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Indirect Comparisons of Efficacy between Combination Approaches in Metastatic Hormone-sensitive Prostate Cancer: A Systematic Review and Network Meta-analysis.
    Sathianathen NJ; Koschel S; Thangasamy IA; Teh J; Alghazo O; Butcher G; Howard H; Kapoor J; Lawrentschuk N; Siva S; Azad A; Tran B; Bolton D; Murphy DG
    Eur Urol; 2020 Mar; 77(3):365-372. PubMed ID: 31679970
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Addition of Docetaxel to Androgen Deprivation Therapy for Patients with Hormone-sensitive Metastatic Prostate Cancer: A Systematic Review and Meta-analysis.
    Tucci M; Bertaglia V; Vignani F; Buttigliero C; Fiori C; Porpiglia F; Scagliotti GV; Di Maio M
    Eur Urol; 2016 Apr; 69(4):563-573. PubMed ID: 26422676
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Abiraterone in "High-" and "Low-risk" Metastatic Hormone-sensitive Prostate Cancer.
    Hoyle AP; Ali A; James ND; Cook A; Parker CC; de Bono JS; Attard G; Chowdhury S; Cross WR; Dearnaley DP; Brawley CD; Gilson C; Ingleby F; Gillessen S; Aebersold DM; Jones RJ; Matheson D; Millman R; Mason MD; Ritchie AWS; Russell M; Douis H; Parmar MKB; Sydes MR; Clarke NW;
    Eur Urol; 2019 Dec; 76(6):719-728. PubMed ID: 31447077
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of baseline serum IL-8 on metastatic hormone-sensitive prostate cancer outcomes in the Phase 3 CHAARTED trial (E3805).
    Harshman LC; Wang VX; Hamid AA; Santone G; Drake CG; Carducci MA; DiPaola RS; Fichorova RN; Sweeney CJ
    Prostate; 2020 Dec; 80(16):1429-1437. PubMed ID: 32949185
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Addition of abiraterone, docetaxel, bisphosphonate, celecoxib or combinations to androgen-deprivation therapy (ADT) for metastatic hormone-sensitive prostate cancer (mHSPC): a network meta-analysis.
    Tan PS; Aguiar P; Haaland B; Lopes G
    Prostate Cancer Prostatic Dis; 2018 Nov; 21(4):516-523. PubMed ID: 29875432
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cost Effectiveness of Systemic Treatment Intensification for Metastatic Hormone-sensitive Prostate Cancer: Is Triplet Therapy Cost Effective?
    Sathianathen NJ; Lawrentschuk N; Konety B; Azad AA; Corcoran NM; Bolton DM; Murphy DG
    Eur Urol Oncol; 2024 Aug; 7(4):870-876. PubMed ID: 38057191
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prostate Radiotherapy in Low-volume Metastatic Hormone-sensitive Prostate Cancer: A Network Meta-analysis.
    Roy S; Fervaha G; Spratt DE; Sun Y; Kishan AU; Loblaw A; Malone S; Ong M; Saad F; Wallis CJD; Morgan SC
    Eur Urol; 2024 Jul; 86(1):10-17. PubMed ID: 38570246
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [New treatment approaches for and ongoing trials in metastatic hormone-sensitive prostate cancer].
    Isgandarov A; Darr C; Posdzich P; Hermann K; Hadaschik BA; Grünwald V
    Urologie; 2023 Apr; 62(4):369-375. PubMed ID: 36823372
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment of metastatic hormone-sensitive prostate cancer: from doublet therapy to triplet therapy.
    Ye SJ; Huang RD; Fei X; Tao ZL; Liu WH; Ma Q
    Postgrad Med J; 2024 Sep; 100(1188):703-708. PubMed ID: 38767468
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Metastatic Hormone-Sensitive Prostate Cancer and Combination Treatment Outcomes: A Review.
    Hussain M; Fizazi K; Shore ND; Heidegger I; Smith MR; Tombal B; Saad F
    JAMA Oncol; 2024 Jun; 10(6):807-820. PubMed ID: 38722620
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 36.